Non-small cell lung cancers remain particularly refractory to current treatments. Thus, characterisation of new molecular targets whose expression during chemotherapy could stop tumour growth, is required. In order to identify these new targets, we applied RT-PCR differential display (RT-PCR-DD) to a non-small cell lung cancer line (NSCLC-N6) treated by an original chemical substance, VT1, capable of arresting the proliferation of NSCLC-N6 cells in G1 phase. This study enabled us to identify a novel RNA, which has a strong homology with a DNA clone (GenBank accession no.: AY166681). This RNA resides in 6p24-p25 within intron 2 of the HEF1 gene, has no apparent open reading frame and may consists of a single large exon. Antisense oligonucleotides indicated that this RNA is involved in the proliferation arrest induced with VT1 treatment in NSCLC-N6 cells. The structure of this novel RNA resembles that of the previous identified extremely long non-coding RNAs which seem to regulate gene expression. Thus, this novel B2 transcript may belong to this new expanding non-coding RNA family.

Download full-text PDF

Source

Publication Analysis

Top Keywords

non-small cell
12
cell lung
12
non-coding rna
8
rna involved
8
involved proliferation
8
proliferation arrest
8
treated original
8
original chemical
8
chemical substance
8
nsclc-n6 cells
8

Similar Publications

LncRNA MANCR is downregulated in non-small cell lung cancer and predicts poor survival.

Discov Oncol

January 2025

Spinal Surgery Department, the Fourth People's Hospital of Jinan, No.50 Normal Road, Tianqiao District, Jinan, 250031, Shandong, China.

Background: It is known that genomic instability contributes to cancer development. Mitotically associated long non-coding RNA (MANCR) has been reported to promote genomic stability, suggesting its involvement in cancers. Therefore, this study was conducted to investigate the role of MANCR in non-small cell lung cancer (NSCLC).

View Article and Find Full Text PDF

The study investigated the effect of casticin on the proliferation of non-small cell lung cancer(NSCLC) H322 cells and explored its molecular mechanism. Firstly, the cell counting kit-8(CCK-8) assay, colony formation assay, and EdU assay were used to detect the effect of casticin on the proliferation capacity of H322 cells under different concentrations and treatment durations. Then, glucose uptake, lactate production, extracellular pH, and oxygen consumption of H322 cells were measured before and after casticin treatment to analyze its impact on glycolysis in NSCLC H322 cells.

View Article and Find Full Text PDF

The emerging landscape and future perspective of SCLC transformation: from molecular mechanisms to therapeutic strategies.

Crit Rev Oncol Hematol

January 2025

Department of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. Electronic address:

Small-cell lung cancer (SCLC) is featured by high malignancy and undesirable prognosis. Transformed SCLC shares several common grounds but differ in biological behavior, molecular mechanism and therapeutic options from typical SCLC. SCLC transformation exerts indispensable role in drug resistance among patients with non-small cell lung cancer (NSCLC) upon various treatment modalities.

View Article and Find Full Text PDF

AMPK: an energy sensor for Non-small cell lung cancer progression and treatment.

Pharmacol Res

January 2025

Department of Pharmacy, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, 519000, China. Electronic address:

Lung cancer (LC) is the leading cause of cancer-related morbidity and mortality in China, with non-small cell lung cancer (NSCLC) accounting for 85% of the overall lung cancer cases. AMP-activated protein kinase (AMPK) is a key regulator of energy balance and homeostasis, and its dysregulation is a common feature in various malignancies, particularly in NSCLC with mutations in Liver kinase B1 (LKB1). Studies have shown that the AMPK signalling pathway has a dual role in NSCLC progression, both inhibiting and promoting the progression of malignant tumours.

View Article and Find Full Text PDF

Background: Osimertinib is the standard first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated NSCLC. However, treatment resistance is inevitable and increased c-Met protein expression correlates with resistance. Telisotuzumab vedotin (Teliso-V) is an antibody-drug conjugate that targets c-Met protein overexpression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!